Dovepress Rindopepimut for the treatment of glioblastoma 97. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as 98. SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002–6007. and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012;103(2):269–273. Core Evidence Publish your work in this journal Core Evidence is an international, peer-reviewed open-access journal evaluating the evidence underlying the potential place in therapy of drugs throughout their development lifecycle from preclinical to post- launch. The focus of each review is to evaluate the case for a new drug or class in outcome terms in specific indications and patient groups. Submit your manuscript here: http://www.dovepress.com/core-evidence-journal Core Evidence 2012:7 Dovepress The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. submit your manuscript | www.dovepress.com Dovepress 103